NCT01549470View on ClinicalTrials.gov

Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC-HIVDNA009-00-VP

Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.

BIOLOGICAL

Placebo vaccine

Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.

Trial Locations (1)

Unknown

Makerere University Walter Reed Project (MUWRP), Kampala

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH